Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Sana Biotechnology Inc (NQ: SANA )

7.500 -0.330 (-4.21%)
Streaming Delayed Price Updated: 12:44 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sana Biotechnology Inc

< Previous 1 2 Next >
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells 
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.